Zhu Yixuan, Liu Chuan, Xu Xiaoming, Ma Xiaoyan, Liu Jiacheng, Zhang Zhiyi, Li Fuchao, Wong Danny Ka-Ho, Fan Zhiwen, Wu Chao, Qi Xiaolong, Li Jie
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing 210008, China.
Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.
J Pers Med. 2023 Mar 20;13(3):554. doi: 10.3390/jpm13030554.
Diabetes mellitus (DM) is a comorbidity commonly presenting with metabolic-dysfunction-associated fatty liver disease (MAFLD); however, few tests for interaction have been reported. Our target was to evaluate the prognostic implications of DM in patients with different forms of MAFLD.
Using data from the Third National Health and Nutrition Examination Survey (NHANES III) in the United States, we screened 14,797 participants aged 20-74 who received ultrasound examinations from 1988-1994. Among them, 4599 patients met the diagnosis of MAFLD, and we defined mortality as the outcome event. Survival analysis of competitive risk events was performed using Cox regression and sub-distributed risk ratio (SHR).
During 21.1 years of follow-up, cardiovascular diseases seemed to be the most common cause of death among MAFLD patients. Of them, DM was present in 25.48% and was independently associated with increased risk of all-cause mortality (HRs: 1.427, 95% CIs: 1.256-1.621, p < 0.001) and cause-specific mortality (cardiovascular-related mortality (HRs: 1.458, 95% CIs: 1.117-1.902, p = 0.005), non-cardiovascular-related mortality (HRs: 1.423, 95% CIs: 1.229-1.647, p < 0.001), and non-cancer-related mortality (HRs: 1.584, 95% CIs: 1.368-1.835, p < 0.001), respectively). Surprisingly, this association was more significant for young patients (p-value for interaction <0.001). Moreover, DM had a greater risk of all-cause and cause-specific mortality among overweight and obese MAFLD patients (p-value for interaction <0.001).
DM increased the risk of all-cause and cause-specific mortality (cardiovascular-related, non-cardiovascular-related, and non-cancer-related) in MAFLD patients, especially in younger patients with excess obesity.
糖尿病(DM)是一种常与代谢功能障碍相关脂肪性肝病(MAFLD)并存的疾病;然而,关于相互作用的检测报道较少。我们的目标是评估DM对不同形式MAFLD患者的预后影响。
利用美国第三次全国健康和营养检查调查(NHANES III)的数据,我们筛选了1988年至1994年接受超声检查的14797名20 - 74岁的参与者。其中,4599名患者符合MAFLD诊断标准,我们将死亡定义为结局事件。采用Cox回归和亚分布风险比(SHR)对竞争风险事件进行生存分析。
在21.1年的随访期间,心血管疾病似乎是MAFLD患者中最常见的死亡原因。其中,DM患者占25.48%,且与全因死亡率增加独立相关(风险比:1.427,95%置信区间:1.256 - 1.621,p < 0.001)以及特定病因死亡率(心血管相关死亡率(风险比:1.458,95%置信区间:1.117 - 1.902,p = 0.005)、非心血管相关死亡率(风险比:1.423,95%置信区间:1.229 - 1.647,p < 0.001)和非癌症相关死亡率(风险比:1.584,95%置信区间:1.368 - 1.835,p < 0.001))。令人惊讶的是,这种关联在年轻患者中更为显著(相互作用p值<0.001)。此外,DM在超重和肥胖的MAFLD患者中全因和特定病因死亡率风险更高(相互作用p值<0.001)。
DM增加了MAFLD患者全因和特定病因死亡率(心血管相关、非心血管相关和非癌症相关)的风险,尤其是在肥胖的年轻患者中。